Serum CXCL10 and CRP Levels in Patients with Acne Vulgaris in Correlation with Disease Severity

NCT06869109 | Not Yet Recruiting DMC

• 1 other identifier: role of CXCL10 and CRP in acne
• Study Type: observational
• Target: 88
• Locations: 1 country
• Sites: 1

Brief Summary

the correlations between CXCL10 levels, CRP, and acne severity scores (e.g., Global Acne Grading System) suggest that CXCL10 could serve as a biomarker of inflammation and acne severity. Understanding the relationship between CXCL10, CRP, and acne severity may offer insights into novel therapeutic strategies targeting inflammatory pathways in acne.

Conditions

Acne Vulgaris

Keywords

acne vulgaris; cxcl10; crp

Outcome Measures

Primary Outcomes (1)

• Correlation of CXCL10 and CRP levels with acne severity (GAG score).

  compare the result of serum cxcl10 and crp with disease severity

  within one year after the result

Secondary Outcomes (2)

• Identify thresholds of CXCL10 and CRP for predicting moderate/severe acne

  within one year after the result

• Explore potential differences based on sex or age groups

  within one year of the result

Study Arms (4)

mild acne group

mild disease severity

Diagnostic Test: serum cxcl10; Diagnostic Test: serum crp

moderate acne group

moderate disease severity

Diagnostic Test: serum cxcl10; Diagnostic Test: serum crp

severe acne group

severe disease severity

Diagnostic Test: serum cxcl10; Diagnostic Test: serum crp

control group

healthy people

Diagnostic Test: serum cxcl10; Diagnostic Test: serum crp

Interventions

serum cxcl10 DIAGNOSTIC_TEST

serum blood sample to measure the cxcl10

control group; mild acne group; moderate acne group; severe acne group

serum crp DIAGNOSTIC_TEST

blood sample to measure crp

control group; mild acne group; moderate acne group; severe acne group

Eligibility Criteria

• Age: 12 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

the patients with acne with different severity

You may qualify if:

• Patients aged 12-40 years diagnosed with acne vulgaris.
• Both genders included.
• Patients with mild, moderate, or severe acne severity as determined by a validated scoring system (e.g., Global Acne Grading System).
• Patients not on systemic acne treatment (e.g., isotretinoin or antibiotics) or anti-inflammatory drugs.

You may not qualify if:

• Patients with autoimmune diseases, systemic illnesses, acute infection or any other chronic inflammatory conditions that may affect CRP or CXCL10 levels.
• Pregnant or lactating individuals.

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assiut University

Asyut, Asyut Governorate, 71515, Egypt

Location

Related Publications (12)

• Abdelrazik YT, Ali FM, Salek MS, Finlay AY. Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI). Br J Dermatol. 2021 Oct;185(4):711-724. doi: 10.1111/bjd.20391. Epub 2021 Jul 22.

  PMID: 33864247 BACKGROUND

• Alsulaimani H, Kokandi A, Khawandanh S, Hamad R. Severity of Acne Vulgaris: Comparison of Two Assessment Methods. Clin Cosmet Investig Dermatol. 2020 Sep 28;13:711-716. doi: 10.2147/CCID.S266320. eCollection 2020.

  PMID: 33061511 BACKGROUND

• Stańkowska A, Bergler-Czop B, Brzezińska-Wcisło L. Interleukins-6, -8 and -12p40 and C-reactive protein levels in patients with acne vulgaris with various severityof skin changes. Dermatology Review/Przegląd Dermatologiczny. 2020;107(4):308-22

  BACKGROUND

• Yang CC, Huang YT, Yu CH, Wu MC, Hsu CC, Chen W. Inflammatory facial acne during uncomplicated pregnancy and post-partum in adult women: a preliminary hospital-based prospective observational study of 35 cases from Taiwan. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1787-1789. doi: 10.1111/jdv.13667. Epub 2016 Apr 22.

  PMID: 27102946 BACKGROUND

• Kutlu O, Karadag AS, Unal E, Kelekci KH, Yalcinkaya Iyidal A, Topaloglu Demir F, Aksoy B, Colgecen E, Tosun M, Emre S, Tatliparmak A, Demirseren DD, Kaya Ozden H, Ozturk M, Ozlu E, Chen W. Acne in pregnancy: A prospective multicenter, cross-sectional study of 295 patients in Turkey. Int J Dermatol. 2020 Sep;59(9):1098-1105. doi: 10.1111/ijd.14999. Epub 2020 Jun 20.

  PMID: 32562263 BACKGROUND

• Ansar W, Ghosh S, Ansar W, Ghosh S. Inflammation and inflammatory diseases, markers, and mediators: role of CRP in some inflammatory diseases. Biology of C reactive protein in health and disease. 2016:67-107

  BACKGROUND

• Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179-86. doi: 10.1002/hep.1840120517.

  PMID: 1699862 BACKGROUND

• Yu H, Zhang B, Zhan Y, Yi Y, Jiang Q, Zhang Q, Wu Y, Wu M. Neutrophil extracellular trap-related mechanisms in acne vulgaris inspire a novel treatment strategy with adipose-derived stem cells. Sci Rep. 2024 Jan 17;14(1):1521. doi: 10.1038/s41598-024-51931-w.

  PMID: 38233540 BACKGROUND

• Bowe WP, Logan AC. Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles. Lipids Health Dis. 2010 Dec 9;9:141. doi: 10.1186/1476-511X-9-141.

  PMID: 21143923 BACKGROUND

• Jin Z, Song Y, He L. A review of skin immune processes in acne. Front Immunol. 2023 Dec 15;14:1324930. doi: 10.3389/fimmu.2023.1324930. eCollection 2023.

  PMID: 38193084 BACKGROUND

• Liang J, Chen Y, Wang Z, Wang Y, Mu S, Zhang D, Wang Z, Zeng W. Exploring the association between rosacea and acne by integrated bioinformatics analysis. Sci Rep. 2024 Feb 6;14(1):3065. doi: 10.1038/s41598-024-53453-x.

  PMID: 38321132 BACKGROUND

• Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012 Jan 28;379(9813):361-72. doi: 10.1016/S0140-6736(11)60321-8. Epub 2011 Aug 29.

  PMID: 21880356 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

blood sample

MeSH Terms

Conditions

Acne Vulgaris

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Study Officials

• Doaa Samir, prof

  Assiut University

  STUDY DIRECTOR

• Ahmed Shawky, prof

  Assiut University

  STUDY DIRECTOR

Central Study Contacts

Dina Essam, physician

CONTACT

+201027664829; dina.14224214@med.aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: physician assiut university student hospital

Study Record Dates

• First Submitted: March 4, 2025
• First Posted: March 11, 2025
• Study Start: March 10, 2025
• Primary Completion: March 10, 2026
• Study Completion: April 10, 2026
• Last Updated: March 11, 2025

Record last verified: 2025-03

Locations

EG (1)